Abstract
Many large epidemiological studies confirmed a positive association between raised serum uric acid (SUA) levels and risk of coronary heart disease (CHD) or cardiovascular disease (CVD) in the general population, among hypertensive patients and those with established CHD, stroke, diabetes and heart failure. There is much controversy concerning the role of SUA as an independent risk factor for CHD as SUA is related to many of the established risk factors for cardiovascular disease including hypertension, dyslipidaemia, obesity and pre-existing disease. The epidemiological evidence suggests that SUA is an independent predictor of CVD in subjects with hypertension and established vascular disease but not in healthy subjects. This evidence suggests that the influence of SUA on CHD is explained by the secondary association of SUA with other established etiological risk factors (hypertension, dyslipidaemia, hyperinsulinaemia, obesity and pre-existing disease). There is no evidence so far to indicate that lowering SUA levels with drug treatment has a beneficial effect on CVD outcome. In summary, there is little support for an independent causal role for SUA in the development of CHD. However, SUA may provide useful prognostic information in subjects with hypertension and vascular disease.
Keywords: Serum uric acid, coronary heart disease, hypertension, epidemiology, risk factors
Current Pharmaceutical Design
Title: Serum Uric Acid and Risk of Coronary Heart Disease
Volume: 11 Issue: 32
Author(s): S. G Wannamethee
Affiliation:
Keywords: Serum uric acid, coronary heart disease, hypertension, epidemiology, risk factors
Abstract: Many large epidemiological studies confirmed a positive association between raised serum uric acid (SUA) levels and risk of coronary heart disease (CHD) or cardiovascular disease (CVD) in the general population, among hypertensive patients and those with established CHD, stroke, diabetes and heart failure. There is much controversy concerning the role of SUA as an independent risk factor for CHD as SUA is related to many of the established risk factors for cardiovascular disease including hypertension, dyslipidaemia, obesity and pre-existing disease. The epidemiological evidence suggests that SUA is an independent predictor of CVD in subjects with hypertension and established vascular disease but not in healthy subjects. This evidence suggests that the influence of SUA on CHD is explained by the secondary association of SUA with other established etiological risk factors (hypertension, dyslipidaemia, hyperinsulinaemia, obesity and pre-existing disease). There is no evidence so far to indicate that lowering SUA levels with drug treatment has a beneficial effect on CVD outcome. In summary, there is little support for an independent causal role for SUA in the development of CHD. However, SUA may provide useful prognostic information in subjects with hypertension and vascular disease.
Export Options
About this article
Cite this article as:
Wannamethee G S., Serum Uric Acid and Risk of Coronary Heart Disease, Current Pharmaceutical Design 2005; 11 (32) . https://dx.doi.org/10.2174/138161205774913200
DOI https://dx.doi.org/10.2174/138161205774913200 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Innate Immunity, Toll-Like Receptors, and Diabetes
Current Immunology Reviews (Discontinued) Biological Active Peptides from Marine Sources Related to Gut Hormones
Current Protein & Peptide Science Nanomaterial Based Approaches for the Diagnosis and Therapy of Cardiovascular Diseases
Current Pharmaceutical Design The Heart Metabolism: Pathophysiological Aspects in Ischaemia and Heart Failure
Current Pharmaceutical Design Thioridazine: The Good and the Bad
Recent Patents on Anti-Infective Drug Discovery Recent Patents in Diagnosis and Treatment for Inborn Errors of Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Antioxidant Response as a Drug Target in Diabetic Neuropathy
Current Drug Targets A Comparative Assessment of Metabolic Syndrome and its Association with Vitamin D and Other Risk Factors in Type 2 Diabetes Mellitus Patients
Current Diabetes Reviews Macrophage-Assisted Inflammation and Pharmacological Regulation of the Cholinergic Anti-Inflammatory Pathway
Current Medicinal Chemistry The Protective Effects of Extra Virgin Olive Oil on Immune-mediated Inflammatory Responses
Endocrine, Metabolic & Immune Disorders - Drug Targets Dendritic Cell Homeostasis in the Regulation of Self-Reactivity
Current Pharmaceutical Design COPD Evaluation: Beyond the Airway Obstruction, a Follow Up
Current Respiratory Medicine Reviews Role of Moving Average Analysis for Development of Multi-Target (Q)SAR Models
Mini-Reviews in Medicinal Chemistry Recombinant Human Insulin-Like Growth Factor-1: A New Cardiovascular Disease Treatment Option?
Cardiovascular & Hematological Agents in Medicinal Chemistry Use of Recombinant Human Erythropoietin as an Antianemic and Performance Enhancing Drug
Current Pharmaceutical Biotechnology ECG Analysis: A Brief Review
Recent Advances in Computer Science and Communications The Role of C-Reactive Protein in Atherosclerotic Cardiovascular Disease: An Overview
Current Vascular Pharmacology The Pathophysiology of Sleep Apnoea: What We have Learned from Animal Models of Chronic Intermittent Hypoxia
Current Respiratory Medicine Reviews Endothelial Expression of MHC Class II Molecules in Autoimmune Disease
Current Pharmaceutical Design Diagnosis of Cardiovascular Diseases Using Retinal Images Through Vessel Segmentation Graph
Current Medical Imaging